SEC filings, financial news outlets

Regeneron Invests $100M in Mammoth for CRISPR-Based Gene Editing Therapies

Apr 25, 2024, 11:30 AM

Regeneron Pharmaceuticals has announced a significant expansion into gene editing by partnering with Mammoth Biosciences. The collaboration aims to research, develop, and commercialize CRISPR-based gene editing therapies for various diseases, targeting multiple tissues and cell types. Regeneron will make a substantial financial commitment, including a $5 million upfront payment and a $95 million equity investment in the CRISPR startup, totaling $100 million. This move is part of Regeneron's broader strategy to deepen its capabilities in genetic medicines, including a recent acquisition in cell therapy and ongoing partnerships focused on developing treatments for rare diseases like transthyretin amyloidosis. Mammoth, which previously developed CRISPR technology for COVID-19 diagnostics, has shifted focus to smaller DNA-cutting enzymes that could be more easily delivered into tissues across the body.